Clinical Trial

Real-World Effectiveness and Pharmacogenetics of Belzutifan in VHL Syndrome: The BELIEVE-VHL Trial

Study acronym: BELIEVE-VHL
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated September 11, 2025 (before its estimated February 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
The BELIEVE-VHL Trial is a prospective real-life study designed to evaluate the therapeutic effects, benefits, and adverse effects of belzutifan, as well as the timing of treatment response and disease progression in patients with von Hippel-Lindau (VHL) syndrome.
Trial Details
NCT Number NCT07167329
Lead Sponsor José Claudio Casali da Rocha
Collaborators: AC Camargo Cancer Center
Conditions Von Hippel Lindau, Von Hippel Lindau Disease, Von Hippel Lindau-Deficient Clear Cell Renal Cell Carcinoma, Hemangioblastoma (HB) of the Central Nervous System (CNS), PNET, Retinal Angiomatous Proliferation, Pheochromocytoma/Paraganglioma, Endolymphatic Sac Tumor
Enrollment 100 participants
Start Date 2024-01-01
Primary Completion 2026-02-01 (estimated)
Study Completion 2030-01-01 (estimated)
Updated on ClinicalTrials.gov 2025-09-11